The evidence behind the Meticulous topical system.
The volume-support technology at the centre of the Meticulous moisturizer is supported by a randomised, placebo-controlled clinical study. In 20 women aged 40–60, a cream containing the active applied twice daily reduced nasolabial fold depth by 9.5% at day 30, measured by 3D profilometry, while the placebo-treated half of the same face worsened by 3.2% over the same period.
That active does not work alone. In our finished formulation it sits at the centre of Adipo Restore Complex™, alongside peptide, barrier-lipid, cellular-defence and hydration pathways, in a moisturizer that is itself one part of the Meticulous Integrated Support Platform™, spanning topical and internal support, built for one specific situation: the skin of someone losing weight quickly on a GLP-1 medication.
We then observed that finished system in use. In an observational study of ten GLP-1 users over 90 days, with four followed to 180, all ten reported improvement in the appearance of their skin, including in firmness, fullness or facial-volume support and in tone and evenness. All ten completed the programme. None discontinued.
The two studies do different jobs. The first is controlled and instrument-measured, but was not conducted in a GLP-1 population. The second is in exactly that population, but is uncontrolled and participant-reported. Neither substitutes for the other, and this document keeps them separate throughout.
This sets out the evidence behind the Meticulous topical system in the form a clinical or regulatory reviewer would expect to see it, including the parts that are inconvenient for us.
The Meticulous topical products are cosmetic products. All claims made are cosmetic, appearance-based claims. No disease, treatment, or structure/function claim is made or intended, and the products are not intended to diagnose, treat, cure or prevent any condition, including any condition associated with GLP-1 therapy.
Healthy looking skin depends on structural support, barrier integrity, cellular resilience and hydration. These needs existed before GLP-1 therapy. The GLP-1 changes the context.
Facial appearance is driven substantially by the superficial and deep fat compartments of the face. As overall body fat decreases, these compartments lose volume and the skin above them has less underlying support. The visible result is flattening through the midface, deeper folds around the nose and mouth, and a less defined jawline.
The same structural pattern is well described in chronological ageing, where it develops gradually over decades. What differs when substantial weight loss occurs over a compressed period is the speed. The change can appear over months rather than years, which is why patients notice it and describe looking older or more tired even while they are pleased with their weight results.
Meticulous is formulated around this specific situation rather than around general anti-ageing. The dermatological effects of GLP-1 receptor agonist therapy are an emerging area of published interest, and the mechanisms are not yet fully characterised in the literature.1
Meticulous was built around a principle that shapes everything below: what is visible on the surface is influenced by what is happening throughout the body and within the skin itself. Inflammatory and oxidative stress, cellular energy, nutrition, sleep, hydration, barrier function and skin structure are interconnected.
These biological needs existed before GLP-1 therapy. The GLP-1 changes the context, not the requirements. As appetite, nutritional intake, weight and body composition change, an individual may encounter a new set of nutritional, cellular and visible structural challenges, while still navigating the same stress, sleep and lifestyle pressures they had before.
| Product | Territory | Role |
|---|---|---|
| Protocol IO | Daytime internal | Whole-body nutritional and cellular support: inflammatory balance, oxidative stress defence, mitochondrial resilience, nutrient support, skin resilience from within |
| Protocol NR | Nighttime internal | Sleep initiation and continuity, nervous system balance, polyphenol antioxidant defence, overnight hydration |
| Longevity Hybrid Defense Serum | External defence | Multi-pathway antioxidant defence, botanical protection, advanced hydration, support for the look of renewed, firmer skin |
| Revolumizing Bioactive Moisturizer | External structure | Support for the appearance of facial volume and firmness, barrier and lipid support, cellular defence, advanced hydration |
Protocol IO and Protocol NR are dietary supplements. Statements regarding them have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
These four products form the Meticulous Integrated Support Platform™. They are not four independent products. Each occupies a defined territory, and their pathways intentionally overlap because human biology is interconnected. The internal products provide nutritional support complementary to the body's own processes. They are not intended to duplicate, enhance or interfere with the pharmacological activity of GLP-1 therapy.
Everything from Section 4 onward concerns the two topical products only. They are designed to be used together and were observed together. The two internal products are described above for context; no evidence in this document applies to them, and no claim here should be read as extending to them.
The Revolumizing Bioactive Moisturizer is built around Adipo Restore Complex™, a proprietary multi-pathway system designed to support the appearance of facial volume, structure and firmness.
At its centre is an amino acid technology held in a phospholipid delivery system. Unlike most actives used in this category, it is not designed to act at the skin surface. That delivery approach was selected to carry the active into the skin rather than leave it at the surface, in support of the appearance of facial volume.
This is the reason the formulation exists. A surface-level actives strategy does not address the change described in Section 2, however well it performs on texture or hydration. Around that centre sit four further pathways: peptide and PDRN technology for firmness and skin quality, ceramides and phospholipids for barrier and lipid support, postbiotic and osmolyte technologies for cellular defence, and layered humectants for sustained hydration.
The supplier has conducted both in vitro and in vivo work characterising how the active behaves. The clinical portion is reported in the next section. The in vitro and mechanistic work behind the active is available for discussion with your technical or regulatory reviewers.
We have deliberately kept the molecular detail out of this document. It is not evasion. We can go deeper in conversation with your reviewers than would be appropriate here. Our view is that a partner-facing document should carry the evidence a reviewer needs to make a decision, and that formulation specifics belong in a conversation rather than in a file that circulates.
The raw material supplier conducted a clinical study on the active. Its design is materially stronger than our own observational work, and we report it here in full because it is the randomised, placebo-controlled part of the evidence base.
| Population | 20 healthy female volunteers, aged 40–60, with nasolabial folds |
| Design | Randomised, placebo-controlled, split-face, with each participant serving as her own control |
| Intervention | Emulsion cream containing 2% active vs. matched placebo, twice daily |
| Duration | 60 days, assessed at days 0, 30 and 60 |
| Measurement | Primos 3D profilometry, dermatologist clinical scoring, participant self-assessment |
| Measure | Active side | Placebo side |
|---|---|---|
| Nasolabial fold depth lower is better | −9.5% shallower | +3.2% deeper |
| Skin roughness lower is better | −5.9% smoother | +3.1% rougher |
| Dermatologist-scored smoothness higher is better | +31.6% smoother | +10.5% smoother |
The figures above are group means. Individual response varied considerably: the supplier reports reductions of up to 37.6% in wrinkle depth and up to 27.5% in roughness among individual participants.
Changes on the treated side were reported as statistically significant (p<0.05); the placebo-treated half of the same face showed no significant variation. Dermatologist-scored smoothness continued to improve at day 60, reaching +42.1% against +10.5% for placebo. Participant self-assessment at day 60 reported skin that felt smoother, firmer, less tired and plumper.
These data are ingredient-level. They were generated by the raw material supplier, in the supplier's own test vehicle, and are not published in the peer-reviewed literature. They substantiate the mechanism and the raw material. They are not a clinical trial of the Meticulous finished product, and no claim about our product rests on them alone.
Ingredient evidence transfers to a finished product only to the extent that the ingredient is present at a comparable level, in a comparable vehicle, applied in a comparable way. That study tested one molecule, at 2%, in a plain emulsion cream, on women who were not losing weight.
Our finished formulation is not that. The active sits inside Adipo Restore Complex™ alongside four other pathways, in a moisturizer that is itself one part of a four-product platform spanning topical and internal support. And it is used by people whose skin is changing for a different reason, and at a different speed.
| Variable | Supplier study | Meticulous |
|---|---|---|
| Active concentration | 2% | Proprietary |
| Vehicle | Plain emulsion cream | Complete formulated moisturizer |
| Application | Twice daily, topical | Twice daily, topical |
| Population | Women 40–60 with nasolabial folds | GLP-1 users, mixed sex, aged 41–62 |
The population difference is the material one, and it is the reason the next section exists. To our knowledge, no controlled study of this active, or a comparable one, in a GLP-1 population has been published. Our own observational work begins to describe that gap. A controlled study would close it.
Scott Kanyok, who formulates the range, is available to take your technical or regulatory reviewers through the science directly.
We observed the finished topical system in use by GLP-1 users. It is described here exactly as it was conducted.
The study, including participant stories, photography and the methodology summary, is published openly at meticulousskincare.com/pages/results.
| Design | Prospective, open-label, single-arm observational study. No control group and no blinding. |
| Participants | 10 adults on GLP-1 medications, aged 41–62, 8 women and 2 men, already noticing changes in their skin |
| Weight change | Approximately 12 lb to 207 lb lost across the group |
| Intervention | Twice-daily use of the serum and moisturizer together |
| Duration | Baseline through 90 days, with check-ins at days 14, 30, 60 and 90. Four participants were followed to 180 days. |
| Assessment | Participant photography, video documentation and structured written questionnaires. All outcomes are participant-reported. No instrumental measurement and no clinician grading were performed. |
| Recruitment | Participants were self-selected. Consent for photography and feedback was obtained from all ten. |
Counts are given rather than percentages. With ten participants, a percentage implies a precision the sample cannot carry.
| Reported outcome | Result |
|---|---|
| Improvement in firmness, fullness or facial-volume support | 10 of 10 |
| Improvement in tone and evenness | 10 of 10 |
| Completed the programme and continued twice-daily use | 10 of 10 |
| Discontinued due to irritation | 0 of 10 |
Images are unretouched and were captured by participants on their own devices; lighting, distance and conditions vary between timepoints and were not standardised to clinical photography conditions. These are individual results and are not presented as typical.
"I have lost 10 pounds between the before-and-after photos, yet my face looks fuller in the 90-day photos." Participant, day 90
"I saw a visible decrease in the depth of my nasolabial folds — my biggest skin-related confidence issue." Participant, day 30
Quotations are participant-authored and used with consent. Individual experiences are not necessarily representative of typical results.
We state these in full, because a reviewer will identify every one of them and because the study is more useful to both parties when its boundaries are explicit.
Read together, these mean the study is evidence of tolerability, adherence, and a consistent directional signal in the target population, and a rationale for a controlled study. It establishes tolerability, adherence and directional signal; causal efficacy is reserved for controlled evaluation.
The Meticulous Study is the first look at this product in a GLP-1 population. The next step is the controlled, instrumented version of it: measured rather than reported, with independent grading. To our knowledge, no such study has been published in this category.
That is the study we intend to run: independent dermatologist grading, standardised clinical photography under controlled conditions, and instrumental measurement: hydration, barrier function and skin elasticity measured by device rather than by questionnaire.
Run within a partner's own patient population, that study would produce something more durable than a marketing asset: a dataset on how that population's skin behaves during treatment. Access to and use of such data, its ownership, any publication, and its governance would be set out in a written agreement between the parties before the study began, with participant consent covering each permitted use.
| Evidence | Supports | Does not support |
|---|---|---|
| Supplier clinical study Randomised, placebo-controlled, instrumented | The mechanism, and the raw material at the concentration tested | Any claim about Meticulous finished products |
| In vitro work Supplier-conducted | Biological plausibility of the mechanism | Any in vivo or finished-product outcome |
| The Meticulous Study Open-label, uncontrolled, n=10 | Tolerability, adherence and directional signal in GLP-1 users | Causal efficacy, comparative claims and typical results — reserved for controlled evaluation |
Our study protocol, questionnaire instruments and per-participant anonymised data are available to your technical or regulatory team on request.
We do not support the drug. We support the person on the drug.
Prepared by Meticulous Skincare. Not for consumer distribution. The descriptions in Section 4 are provided for technical evaluation and are not approved consumer claim language.